Enanta's 15min chart shows a KDJ Death Cross and Bearish Marubozu pattern.

Enanta's 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu at 08/27/2025 11:45. This indicates a shift in momentum towards the downside, with potential for further decline. Sellers currently dominate the market, and bearish momentum is likely to continue.

Pfizer Inc. (PFE) experienced a modest 0.24% increase in its stock price on August 20, 2025, reaching $25.33, despite ongoing legal and clinical setbacks. The company's stock traded with a volume of $0.97 billion, ranking 92nd in the market [1].

The stock's rise came amidst a patent infringement lawsuit filed by Enanta Pharmaceuticals in the European Union's Unified Patent Court. Enanta alleges that Pfizer's COVID-19 treatment, Paxlovid, infringes on its European Patent No. EP 4 051 265. This lawsuit follows a dismissed U.S. case that Enanta plans to appeal. The potential impact on Paxlovid's revenue stream remains significant, although Pfizer maintains confidence in its intellectual property [1].

Adding to the challenges, Pfizer reported a Phase III trial failure for a sickle cell disease candidate acquired in 2022. This drug was a key growth hope for the company's oncology division. Despite strong Q2 2025 results driven by 71% growth in Paxlovid sales and 95% higher Comirnaty vaccine revenue, these setbacks highlight risks in Pfizer's R&D pipeline [1].

Analysts warn that the dual challenges may weigh on investor sentiment, but the stock's modest rise suggests market confidence in its broader portfolio and capital allocation strategy [1].

Separately, Enanta Pharmaceuticals has filed a patent infringement lawsuit against Pfizer in the European Union's Unified Patent Court, alleging that Pfizer's COVID-19 antiviral, Paxlovid, infringes on Enanta's European Patent No. EP 4 051 265. The lawsuit, action number 35071/2025, targets Pfizer's activities in 18 EU countries and is based on Enanta's patent application for coronavirus protease inhibitors [2].

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) filed a patent infringement lawsuit against Pfizer Inc. in the European Union's Unified Patent Court (UPC), alleging that Pfizer's COVID-19 antiviral, Paxlovid, infringes on Enanta's European Patent No. EP 4 051 265. The lawsuit, action number 35071/2025, targets Pfizer's activities in 18 EU countries and is based on Enanta's patent application for coronavirus protease inhibitors [2].

References:
[1] https://www.ainvest.com/news/pfizer-rises-0-24-legal-clinical-setbacks-trading-volume-ranks-92nd-2508/
[2] https://www.ainvest.com/news/enanta-sues-pfizer-covid-19-treatment-patent-infringement-europe-2508/